Asset 2 Conferences
Gu Liangcai - profile picture

Liangcai Gu

Harvard Medical School, US

Dr. Liangcai Gu completed his Ph.D. in Medicinal Chemistry with Professor David Sherman at University of Michigan in 2008. He in vitro reconstituted a 65-enzyme biosynthetic pathway of curacin A, an anticancer bacterial metabolite. His work led to discoveries of a set of unexpected biochemical reactions important to polyketide diversification and provided a basis for engineering of the enzymes into other pathways to produce valuable chemicals. He then conducted his postdoctoral research in proteomics and next-generation sequencing techniques in Professor George Church laboratory at Harvard Medical School. He developed an in situ DNA sequencing-based molecular interactome technique, single-molecular-interaction sequencing (SMI-seq), which can largely improve the throughput, multiplexing capability, quality and cost-effectiveness of protein interactome profiling, and were shown to be useful in quantification of interactome changes in human diseases, ultra-low cost small molecule drug screening, and selection of large-scale affinity reagents for proteomics applications.